# A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

> **NCT03139513** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 200 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT03139513
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-27
- **Primary completion:** 2018-08-22
- **Final completion:** 2018-08-22
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2019-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03139513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03139513, "A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03139513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*